SEC Form 4/A · accession 0000919574-16-009136
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Period of report
Sep 29, 2015
Accepted (ET)
Jan 11, 2016 · 7:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.001 par valueF1,F4 | Sep 29, 2015 | P | 317,548 | $4.56 | A | 17,568,058 | I | See footnote |
| Common stock, $0.001 par valueF2,F4 | Sep 30, 2015 | P | 182,452 | $4.67 | A | 17,750,510 | I | See footnote |
| Common stock, $0.001 par valueF3,F4 | Oct 1, 2015 | P | 100,140 | $4.50 | A | 17,850,650 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This constitutes the weighted average purchase price. The prices range from $4.45 to $4.71. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2This constitutes the weighted average purchase price. The prices range from $4.54 to $4.77. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This constitutes the weighted average purchase price. The prices range from $4.44 to $4.63. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F4These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.